| Literature DB >> 26230583 |
Martha L Slattery1, Daniel F Pellatt1, Lila E Mullany1, Roger K Wolff1.
Abstract
Several diet and lifestyle factors may impact health by influencing oxidative stress levels. We hypothesize that level of cigarette smoking, alcohol, anti-inflammatory drugs, and diet alter gene expression. We analyzed RNA-seq data from 144 colon cancer patients who had information on recent cigarette smoking, recent alcohol consumption, diet, and recent aspirin/non-steroidal anti-inflammatory use. Using a false discovery rate of 0.1, we evaluated gene differential expression between high and low levels of exposure using DESeq2. Ingenuity Pathway Analysis (IPA) was used to determine networks associated with de-regulated genes in our data. We identified 46 deregulated genes associated with recent cigarette use; these genes enriched causal networks regulated by TEK and MAP2K3. Different differentially expressed genes were associated with type of alcohol intake; five genes were associated with total alcohol, six were associated with beer intake, six were associated with wine intake, and four were associated with liquor consumption. Recent use of aspirin and/or ibuprofen was associated with differential expression of TMC06, ST8SIA4, and STEAP3 while a summary oxidative balance score (OBS) was associated with SYCP3, HDX, and NRG4 (all up-regulated with greater oxidative balance). Of the dietary antioxidants and carotenoids evaluated only intake of beta carotene (1 gene), Lutein/Zeaxanthine (5 genes), and Vitamin E (4 genes) were associated with differential gene expression. There were similarities in biological function of de-regulated genes associated with various dietary and lifestyle factors. Our data support the hypothesis that diet and lifestyle factors associated with oxidative stress can alter gene expression. However genes altered were unique to type of alcohol and type of antioxidant. Because of potential differences in associations observed between platforms these findings need replication in other populations.Entities:
Mesh:
Year: 2015 PMID: 26230583 PMCID: PMC4521956 DOI: 10.1371/journal.pone.0134406
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Description of study population.
| Overall | |||
|---|---|---|---|
| N | % | ||
| Sex | |||
| Male | 80 | 55.6% | |
| Female | 64 | 44.4% | |
| Smoking Status | |||
| Never | 60 | 41.7% | |
| Former | 65 | 45.1% | |
| Current | 19 | 13.2% | |
| Recent NSAID Use | |||
| No | 89 | 62.7% | |
| Yes | 53 | 37.3% | |
| Alcohol Long Term and Current (gm/day) | |||
| Low | 53 | 36.8% | |
| Mod | 68 | 47.2% | |
| High | 23 | 16.0% | |
| Beer Long Term & Current (gm/day) | |||
| Low | 88 | 61.1% | |
| Mod | 38 | 26.4% | |
| High | 18 | 12.5% | |
| Wine Long Term & Current (gm/day) | |||
| Low | 74 | 51.4% | |
| Mod | 47 | 32.6% | |
| High | 23 | 16.0% | |
| Liquor Long Term & Current (gm/day) | |||
| Low | 76 | 52.8% | |
| Mod | 44 | 30.6% | |
| High | 24 | 16.7% | |
| Median | Inter-quartile Range | ||
| Beta carotene (mcg/1000 KCAL) | |||
| Low | 912.3 | (668.7, 1058.6) | |
| Intermediate | 1882.1 | (1550.4, 2055.5) | |
| High | 3287.4 | (2647.2, 4583.7) | |
| Lutein + Zeaxanthin (mcg/1000 KCAL) | |||
| Low | 622.9 | (530.2, 745.9) | |
| Intermediate | 1014.3 | (918.7, 1081.7) | |
| High | 1650.0 | (1388.6, 2172.1) | |
| Lycopene (mcg/1000 KCAL) | |||
| Low | 1424.5 | (1075.8, 1846.6) | |
| Intermediate | 2809.5 | (2428.2, 3133.7) | |
| High | 4723.0 | (3994.0, 5891.7) | |
| Total Alpha Tocopherol (mg/1000 KCAL) | |||
| Low | 3.1 | (2.8, 3.3) | |
| Intermediate | 4.1 | (4.0, 4.4) | |
| High | 5.4 | (5.0, 6.4) | |
| Vitamin C (mg/1000 KCAL) | |||
| Low | 37.0 | (32.2, 44.7) | |
| Intermediate | 61.6 | (56.1, 65.8) | |
| High | 109.4 | (88.5, 132.2) | |
| Oxidative Balance Score | |||
| Low | 10.0 | (8.8, 11.0) | |
| Intermediate | 14.0 | (13.0, 14.8) | |
| High | 17.5 | (16.0, 19.0) | |
1Categories are based on tertiles of the population of approximately 48 people per category
Causal Networks associated with recent cigarette smoking.
| Network | Molecules in Network | Score | Focus Molecules | Top Diseases and Functions |
|---|---|---|---|---|
| 1 | 3',5'-cyclic-GMP phosphodiesterase, | 30 | 13 | Cell Morphology, Cellular Development, Endocrine System Development and Function |
| 2 |
| 24 | 11 | Cellular Growth and Proliferation, Organismal Development, Cellular Function and Maintenance |
| 3 | ARVCF, BARX1, | 24 | 11 | Lipid Metabolism, Small Molecule Biochemistry, Vitamin and Mineral Metabolism |
1Genes in bold were upregulated in our data while genes underlined were down-regulated in our dataset
Fig 1Causal Networks identified by IPA where differentially expressed genes were enriched by recent cigarette smoking.
Fig 1A. TEK causal network. Fig 1B. PEBP4 causal network. Fig 1C. MAP2K3 causal network.
Associations between alcohol and gene expression.
| Gene | Average Adjusted Count, Low Tertile Group | Average Adjusted Count, High Tertile Group | Fold Change | P Value | Q Value | Function/known pathways or disease relationships |
|---|---|---|---|---|---|---|
|
| ||||||
|
| 51.32 | 71.20 | 1.39 | 3.63E-05 | 0.076 | Induces phyphorylation of p38 MAP kinases and may impact outcome of ER stress response |
|
| 23.02 | 42.18 | 1.83 | 7.55E-05 | 0.092 | Encodes a calcium dependent protein; regulation of tumor necrosis factor |
|
| 27.52 | 50.72 | 1.84 | 4.28E-05 | 0.076 | Cellular calcium ion homeostasis; cell-to-cell sginaling; regulation of hormone levels such as insulin; mood disorders and biopolar disease |
|
| 54.14 | 34.24 | 0.63 | 5.00E-05 | 0.076 | Regulation of cell cycle process; personality disorders; diabetes |
|
| 3579.58 | 19213.39 | 5.37 | 3.82E-06 | 0.023 | Alter biologic activity of RNA; mediates MAPK signaling |
|
| ||||||
|
| 20.13 | 38.32 | 1.90 | 1.48E-06 | 0.017 | Required for efficient transcription inition by RNA polymerase I; ERKA and AKT activation (mTOR- signaling pathway |
|
| 0.28 | 3.13 | 11.18 | 2.84E-05 | 0.083 | Inflammatory response; this cytokine isdown regulates macrophage activity thereby inhibits the production of pro-inflammatory cytokines and chemokines. Involved in ERK signaling and AKT signaling PAK Pathway; asthma |
|
| 0.85 | 3.44 | 4.04 | 1.90E-05 | 0.067 | Apoptosis; protein folding; gamete generation; |
|
| 5.64 | 11.84 | 2.10 | 1.10E-05 | 0.048 | Negative regulation of cell growth; positive regulation of apoptotic process; response to radiation |
|
| 0.08 | 3.16 | 39.85 | 1.99E-06 | 0.017 | Cell surface receptor linked signal transduction; neurological system process; cognition; Olfactory Signaling Pathway; Signaling by G protein coupled receptors (GPCR) |
|
| 15.16 | 6.96 | 0.46 | 7.25E-06 | 0.042 | Endopeptidase activity; immune response; metabolioc processes; cell cycle, mitotic pathways |
|
| ||||||
|
| 2.10 | 7.80 | 3.72 | 5.62E-07 | 0.010 | Cellular functions including scavenging reactive oxygen species; neurotransmission; oxodpredictase activity; Involved in cytochrome p450 pathways; biological oxidation pathway; and metabolism |
|
| 3.16 | 0.42 | 0.13 | 1.86E-05 | 0.065 | Member of tetraspanin family; structural molecular activity; epithelial cell differentiation |
|
| 11.88 | 5.50 | 0.46 | 3.26E-05 | 0.095 | tRNA metabolic process regulation of translation fideltiy; hydrolase activity |
|
| 56.16 | 38.18 | 0.68 | 7.40E-06 | 0.050 | Blood coagulation; hemostatsis, response to wounding |
|
| 0.36 | 3.37 | 9.46 | 1.31E-05 | 0.057 | Not available |
|
| 3.66 | 12.26 | 3.35 | 8.53E-06 | 0.050 | Neuroprotective and antipoptotic factor |
|
| ||||||
|
| 6.44 | 1.31 | 0.20 | 3.03E-06 | 0.024 | Chemokine activity; immune response; inflammatory response; chemokine signaling; signaling by GPCR |
|
| 43.96 | 29.27 | 0.67 | 2.48E-05 | 0.097 | Cell proliferation; negative regulation of transcritpion from RNA polymerase II promoter; packaging of telomere ends; Development NOTCH1-mediated pathway for NFKB activity |
|
| 11.17 | 8.87 | 0.79 | 8.95E-07 | 0.014 | Symporter activity; ion transport; |
|
| 29.31 | 51.19 | 1.75 | 2.44E-05 | 0.097 | Cellular calcium ion homeostasis; cell-to-cell sginaling; regulation of hormone levels such as insulin; mood disorders and biopolar disease |
1P values are raw p values
2Q Value is the smallest FDR at which this gene is called significant.
Fig 2HEATMAP of differentially expressed genes by type of alcohol intake.
Diet and oxidative balance score associated with differences in gene expression between the upper and lower tertile of expression where the False Discovery Rate (FDR) was set to <0.10.
| Gene | Average Adjusted Count, Low Tertile Group | Average Adjusted Count, High Tertile Group | Fold Change | P Value | Q Value | Function/known pathways or disease relationships |
|---|---|---|---|---|---|---|
|
| ||||||
|
| 4.48 | 9.46 | 2.11 | 3.25E-06 | 0.057 | Cell surface receptor linked signal transduction, G-protein coupled receptor (GPCR) protein signaling pathway |
|
| ||||||
|
| 19.37 | 28.65 | 1.48 | 4.27E-05 | 0.096 | Cell Cycle processes; protein binding involved in protein folding; Parkin-Ubiquitin Proteasomal System Pathway |
|
| 92.37 | 67.78 | 0.73 | 6.12E-05 | 0.096 | Biological Processes |
|
| 36.19 | 57.57 | 1.59 | 1.38E-05 | 0.096 | Transcription regulation; DNA binding; direct p53 effectors pathway |
|
| 15.68 | 22.09 | 1.41 | 4.37E-05 | 0.096 | Endonuclease activity; nucleic acid binding; hydrolase activity |
|
| 64.53 | 29.45 | 0.46 | 5.76E-05 | 0.096 | Response to hypoxia; acute inflammatory response; defense response; pathways include hemostasis and FOXA1 transcription factor network |
|
| ||||||
|
| 8.84 | 17.73 | 2.01 | 2.95E-05 | 0.097 | Protein amino acid dephosphorylation; |
|
| 29.29 | 48.49 | 1.66 | 1.03E-05 | 0.097 | Cytokinesis, cell cycle; cell division; required for normal organization of the actin cytoskeleton; associated with acute myeloid leukemia; pathway include bacterial invasion of epithelial cells |
|
| 6.65 | 13.28 | 2.00 | 2.92E-05 | 0.097 | Metabolic processes; glucuronsyltransferase activity |
|
| 29.73 | 47.28 | 1.59 | 1.78E-05 | 0.097 | Protein kinase binding; antigen receptor-coupled tyrosine kinase; response to hormones; pathways include immune response Fc epsilon RI pathway |
|
| ||||||
|
| 9.89 | 18.47 | 1.87 | 1.81E-05 | 0.09 | Protein transporter activity; intracellular protein transport |
|
| 11.59 | 6.25 | 0.54 | 4.47E-06 | 0.05 | Cellular protein metabolic process; nervous system development protein linked glycosylation |
|
| 14.53 | 22.99 | 1.58 | 2.51E-05 | 0.09 | Metal ion binding; apoptotic process; cell cycle; TP53 signaling pathway |
|
| ||||||
|
| 16.27 | 28.24 | 1.74 | 1.48E-06 | 0.026 | Cell Cycle Process; cell division; DNA binding |
|
| 2.77 | 5.08 | 1.84 | 1.56E-05 | 0.091 | Regulation of transcription; DNA binding |
|
| 5.61 | 11.27 | 2.01 | 8.55E-06 | 0.075 | Growth factor activity |
1No differentially expressed genes with FDR <0.1 identified for Vitamin C and lycopene
2P values are raw p values
3Q Value is the smallest FDR at which this gene is called significant.
Fig 3HEATMAP of differentially expressed genes by antioxidants and carotenoids.